Cancer incidence and mortality after heart transplantation – A population-based national cohort study

Jäämaa‐Holmberg, Salla; Salmela, Birgitta; Lemström, Karl; Pukkala, Eero; Lommi, Jyri

doi:10.1080/0284186x.2019.1580385

Cited by 36 publications

(38 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Supplementary Table S3 provides details of the included studies, which involved e1848068-2 a total of 2,105,122 solid organ transplant recipients and reported 45 types of site-specific cancer. Of them, 52 studies 7,8,75 provided SIRs of multiple cancers of solid organ transplantations (11 for multiple organs, 7,8,[17][18][19][20][21][22][23][24][25] 19 for kidney, [26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44] 16 for liver, [45][46][47][48][49][50][51][52][53][54][55]75 7 for heart and/or lung [60][61][62][76]…”

Section: Systematic Search and Study Characteristicsmentioning

confidence: 99%

Cancer Risks in Solid Organ Transplant Recipients: Results from a Comprehensive Analysis of 72 Cohort Studies

Huo

et al. 2020

OncoImmunology

View full text Add to dashboard Cite

Understanding the cancer risks in different transplant recipients helps early detection, evaluation, and treatment of post-transplant malignancies. Therefore, we performed a meta-analysis to determine the cancer risks at multiple sites for solid organ transplant recipients and their associations with tumor mutation burden (TMB), which reflects the immunogenicity. A comprehensive search of PubMed, Web of Science, EMBASE, Medline, and Cochrane Library was conducted. Random effects models were used to calculate the standardized incidence ratios (SIRs) versus the general population and determine the risks of different cancers. Linear regression (LR) was used to analyze the association between the SIRs and TMBs. Finally, seventy-two articles met our criteria, involving 2,105,122 solid organ transplant recipients. Compared with the general population, solid organ transplant recipients displayed a 2.68-fold cancer risk (SIR 2.68; 2.48-2.89; P <.001), renal transplant recipients displayed a 2.56-fold cancer risk (SIR 2.56; 2.31-2.84; P <.001), liver transplant recipients displayed a 2.45-fold cancer risk (SIR 2.45; 2.22-2.70; P <.001), heart and/or lung transplant recipients displayed a 3.72-fold cancer risk (SIR 3.72; 3.04-4.54; P <.001). The correlation coefficients between SIRs and TMBs were 0.68, 0.64, 0.59, 0.79 in solid organ recipients, renal recipients, liver recipients, heart and/or lung recipients, respectively. In conclusion, our study demonstrated that solid organ transplant recipients displayed a higher risk of some site-specific cancers, providing individualized guidance for clinicians to early detect, evaluate, and treat cancer among solid organ transplantation recipients. In addition, the increased cancer risk of solid organ transplant recipients is associated with TMB, suggesting that iatrogenic immunosuppression may contribute to the increased cancer risk in transplant recipients. (PROSPERO ID CRD42020160409).

show abstract

Section: Systematic Search and Study Characteristicsmentioning

confidence: 99%

Cancer Risks in Solid Organ Transplant Recipients: Results from a Comprehensive Analysis of 72 Cohort Studies

Huo

et al. 2020

OncoImmunology

View full text Add to dashboard Cite

show abstract

“…27 A study of 479 HT patients from the Finnish Cancer Registry showed a standardized incidence ratio (SMR) of 6 for all cancers in HT patients compared to the general Finnish population but no increase in the incidence of PC specifically. 28 Considering the available data, we suspect that the PC-specific mortality in a patient with very low or low-risk LPC undergoing HT to be exceedingly low, particularly if they are subsequently treated with definitive therapy (surgical prostatectomy or radiotherapy).…”

Section: Discussionmentioning

confidence: 99%

Heart transplantation in patients with localized prostate cancer—Are we denying a life‐saving therapy due to an indolent tumor?

Raikhelkar

Pham

Lourenço

et al. 2020

Clinical Transplantation

View full text Add to dashboard Cite

Prostate Cancer (PC) is the most common non-cutaneous cancer in adult men with over 175 000 new cases diagnosed yearly in the United States. 1 The majority of these cases (about 90%) consist of localized prostate cancer (LPC), which is diagnosed in asymptomatic patients found to have to an abnormal elevation in prostate-specific antigen (PSA) and disease confined to prostate gland. The prognosis for patients with LPC is excellent with an estimated 10-year survival from PC-related death of 99%. 2 Heart transplantation (HT) remains the gold standard treatment for patients with advanced heart failure (AHF). Patients with AHF have a dismal prognosis without advanced therapies for heart failure, with an estimated survival as low as 8% at 2 years. 3 All forms of cancer, including PC, remain a relative contraindication for HT due to the risk of rapid progression in the setting of immunosuppression. 4 The degree of utilization of HT in patients with AHF and concurrent LPC is unknown. The aim of this study was to assess the current status of HT in patients with LPC in the United States.

show abstract

“…During the first 5 days, ATG was administered, followed by methylprednisolone associated with cyclosporine and mycophenolate or cyclosporine and everolimus or, after 2008, tacrolimus [49].…”

Section: Methodsmentioning

confidence: 99%

Post-Transplant Lymphoproliferative Diseases in an Elderly Population Who Underwent Cardiac Transplantation: Role of Physical Activity Rehabilitation Program

Sica¹,

Sagnelli²,

Fasano³

et al. 2019

Preprint

View full text Add to dashboard Cite

The incidence of post transplantation lymphoproliferative disorders (PTLDs) and other neoplasms in organ transplant patients is higher than in the non-transplanted population. This event is more frequent in older subjects, due, at least in part, to the immune dysfunction induced by immunosuppressants administered to prevent rejection. Alterations of the immune system mechanisms of protection against carcinogenesis appear to be the key role in the in the pathogenesis of these neoplasms.The data of our study on the incidence of neoplasms occurred during a long-term follow-up in an elderly population after they underwent cardiac transplantation. This study gives, also evidence of the favorable effect of physical activity programs on cardiorespiratory and psychomotor function.

show abstract

Cancer incidence and mortality after heart transplantation – A population-based national cohort study

Cited by 36 publications

References 33 publications

Cancer Risks in Solid Organ Transplant Recipients: Results from a Comprehensive Analysis of 72 Cohort Studies

Cancer Risks in Solid Organ Transplant Recipients: Results from a Comprehensive Analysis of 72 Cohort Studies

Heart transplantation in patients with localized prostate cancer—Are we denying a life‐saving therapy due to an indolent tumor?

Post-Transplant Lymphoproliferative Diseases in an Elderly Population Who Underwent Cardiac Transplantation: Role of Physical Activity Rehabilitation Program

Contact Info

Product

Resources

About